July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Postnatal Induction of PAX6 to Alleviate Aniridia Manifestations
Author Affiliations & Notes
  • Behnam Rabiee
    Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois, United States
  • Xiang Shen
    Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois, United States
  • Khandaker N Anwar
    Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois, United States
  • Ilham Putra
    Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois, United States
  • Neda Afsharkhamseh
    Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois, United States
  • Sayena Jabbehdari
    Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois, United States
  • Ghasem Yazdanpanah
    Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois, United States
  • James D Lauderdale
    Department of Cellular Biology, University of Georgia, Athens, Georgia, United States
  • Mark Rosenblatt
    Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois, United States
  • Ali R Djalilian
    Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois, United States
  • Footnotes
    Commercial Relationships   Behnam Rabiee, University of Illinois at Chicago (P); Xiang Shen, None; Khandaker N Anwar, None; Ilham Putra, None; Neda Afsharkhamseh, None; Sayena Jabbehdari, None; Ghasem Yazdanpanah, None; James Lauderdale, None; Mark Rosenblatt, None; Ali Djalilian, University of Illinois at Chicago (P)
  • Footnotes
    Support  This work was supported by R01 EY024349 (ARD) and Core grant EY01792 from NEI/NIH, Vision For Tomorrow (ARD), unrestricted grant to the department from Research to Prevent Blindness, and Eversight. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the abstract.
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 4118. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Behnam Rabiee, Xiang Shen, Khandaker N Anwar, Ilham Putra, Neda Afsharkhamseh, Sayena Jabbehdari, Ghasem Yazdanpanah, James D Lauderdale, Mark Rosenblatt, Ali R Djalilian; Postnatal Induction of PAX6 to Alleviate Aniridia Manifestations. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4118.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Aniridia is a congenital panocular condition caused by a mutation in one copy of the PAX6 gene. Although the ocular problems begin in utero and are present at birth, we hypothesized that early postnatal stimulation of the normal copy of PAX6 may prevent or reduce further progression of the disease.

Methods : By a chemical screen, we identified compound X (patent pending, to be disclosed at presentation) and evaluated its effect on PAX6 expression by RT-PCR and western blot in human corneal epithelial cells (HCEC). In vivo, we treated a mouse model of aniridia (Pax6Sey-Neu/+) with oral or topical compound X or vehicle, from postnatal day (P)5 to P30. Wild type (WT) littermates were used as normal reference. OCT and slit lamp images were used to compare the corneal epithelial/stromal thickness, clarity and scarring. H&E and immunostaining with PAX6 and Cytokeratin (CK) 12 were used to compare the morphology, protein expression and differentiation. ERG was conducted to assess retinal function.

Results : Compound X increased PAX6 mRNA and protein expressions in HCEC (2.7±0.2 & 3.0±0.3 folds). P30 PAX6 staining confirmed increase in PAX6 protein expression in corneas with both oral (2.3±0.2 folds) and topical (2.5±0.1 folds) methods (P<0.001). Corneal scarring was less in both oral (2.1±0.4% vs. 11.2±4.0%, P<0.001) and topical (2.3±0.6% vs. 10.6±2.5%, P<0.001) groups compared to vehicle controls. Corneal epithelial thickness at P30 was significantly greater than control in both oral (24.7±4.1µm vs. 15.2±1.5µm, P<0.001) and topical (25.5±4.7µm vs. 14.0±1.5µm, P<0.001) groups (WT: 50.5±1.1µm). Corneal stromal thickness at P30 was significantly less than control in both oral (80.2±25.8µm vs. 160.3±11.8µm, P<0.001) and topical (106.9±31.7µm vs. 173.6±18.1µm, P<0.001) groups (WT: 75.8±3.6µm). Both treatment groups showed a more similar histological pattern to normal. P30 CK12 immunostaining and P90 corneal whole mount staining showed better corneal epithelial differentiation in both treatment groups compared to controls (WT CK12 intensity: 100%; oral: 64±3% vs. 31±6%, P<0.01; topical: 69±32% vs. 34±13%, P<0.05). P90 ERG showed increased a and b waves in topical group compared to control (P<0.05).

Conclusions : Early postnatal induction of PAX6 can alleviate several manifestations of aniridia. This approach can potentially be used to partially treat and/or prevent aniridia, particularly the corneal disease which is known to be progressive.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×